Potential predictive biomarkers including microsatellite instability (MSI) status, combined positive score (CPS) of PD-L1 expression, tumor mutational burden (TMB) and Epstein-Barr virus (EBV) status have thus far been demonstrated to predict response to immunotherapy [26, 27]. The gene discussed is CD274; the disease is neoplasm.